New Treatment for Advanced Prostate Cancer

Advanced prostate cancer patients treated with cabazitaxel achieved significantly longer overall survival than did those treated with mitoxantrone.  The clinical study sought to find the best treatment for patients with advanced disease after they have completed docetaxel treatment.  Up until now, doctors have used various treatments at this stage including docetaxel retreatment, or using other chemotherapies such as mitoxantrone, or hormonal treatments such as ketoconazole.  The new study involved men with metastatic castration-resistant prostate cancer, and compared mitoxantrone with cabazitaxel.  It found Cabazitaxel-treated patients achieved longer overall survival, longer progression-free survival, and higher objective tumor and prostate-specific antigen responses.